meningococcal group B Vaccine (rDNA, component, adsorbed)

This medicine is authorised for use in the European Union.


Bexsero is a vaccine used to protect individuals from the age of two months against invasive meningococcal disease caused by one group of the bacterium Neisseria meningitidis (group B). Invasive disease occurs when the bacteria spread through the body causing serious infections such as meningitis (infection of the membranes that surround the brain and spine) and septicaemia (blood infection).

Bexsero contains parts of the bacteria N. meningitidis group B.

This EPAR was last updated on 19/07/2023

Authorisation details

Product details
Agency product number
Active substance
  • outer membrane vesicles from neisseria meningitidis group b (strain nz 98/254)
  • recombinant Neisseria meningitidis group B fHbp fusion protein
  • recombinant Neisseria meningitidis group B NadA protein
  • recombinant Neisseria meningitidis group B NHBA fusion protein
International non-proprietary name (INN) or common name
meningococcal group B Vaccine (rDNA, component, adsorbed)
Therapeutic area (MeSH)
Meningitis, Meningococcal
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
GSK Vaccines S.r.l.
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Via Fiorentina, 1
IT-53100 Siena

Product information

26/04/2023 Bexsero - EMEA/H/C/002333 - WS2365

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Meningococcal vaccines

Therapeutic indication

Active immunisation against invasive disease caused by Neisseria meningitidis serogroup-B strains.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating
4 ratings
1 rating